David Moatazedi

David Moatazedi has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Evolus, Inc. and Biomerica Inc. We count 32 filings; the first trade dates from 10 August 2021 and the latest from 2 September 2026.

Market trades split into 1 purchase (€14k) and 21 sales (€9.8M). The net balance comes to €9.8M on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 9 share grants and 1 option exercise. 2026 to date brings 1 purchase and 2 sales.

The latest filing, published on 4 September 2026, reports an open-market sale of €820k in Evolus, Inc. The last insider purchase was made public on 27 August 2026, 51 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.